CancerPACT Cancer Patients Alliance for Clinical Trials

Transcription

1 TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Cancer Clinical Trials in the Salinas Valley Summer 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.3 3. Gastrointestinal p.3 4. Gynecologic p.4 5. Head & Neck p.4 6. Lung p.5 7. Melanoma p.6 8. Prostate p.6 9. Urologic p.7 II. Hematologic Cancers 1. Leukemia p.8 2. Lymphoma p.9 3. Myeloma p.10 III. Other p.11 I. Solid Tumors 1. Breast Cancer 1. CALGB Phase III Randomized Study of Two Different Schedules of Adjuvant Cyclophosphamide and Doxorubicin Versus Paclitaxel in Women With Operable Breast Cancer and 0-3 Positive Axillary Lymph Nodes 2. CALGB40302 Phase III Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial for Postmenopausal Women with Estrogen-Receptor Positive Advanced Breast Cancer Salinas Valley Memorial Hospital, and

2 2 3. E1105 Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer 4. E5103 Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Nod Negative Breast Cancer 5. CAN-NCIC-MA27 Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer 6. NCIC-CTG MA27B The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density in Postmenopausal Women with Primary Breast Cancer 7. S0221 Phase III Trial of Continuous Schedule AC + G Vs Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer 8. S0226 Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer 9. S0230 Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer 10. S0300 Randomized Placebo-Controlled Biomarker Modulation Trial Using Celecoxib in Premenopausal Women at High Risk for Breast Cancer 11. S0307 Phase III Randomized Study of Adjuvant Zoledronate Versus Clodronate Versus Ibandronate in Women With Resected Primary Stage I-III Adenocarcinoma of the Breast 12. S0500 Phase III Randomized Study of Treatment Decision Making Based on Levels of Circulating Tumor Cells in Women With Metastatic Breast Cancer Undergoing Chemotherapy 13. NSABP B-39 A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer 14. S0622 Phase II Studies of Two Different Schedules of Dasatinib (NSC ) in Bone- Metastasis Predominant Metastatic Breast Cancer 15. N063D Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) study: A Randomised, Multi-Centre, Open-Label, Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer 16. IBCSG-2502 Phase III Randomized Study of Triptorelin and Exemestane Versus Triptorelin and Tamoxifen in Premenopausal Women With Endocrine-Responsive Breast Cancer 17. E1104 Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer 18. PACCT-1 Genomic Profiling for Breast Cancer in Node Negative, ER-Positive and /or PR- Positive Breast Cancer Candidate for Adjuvant Cytotoxic Therapy in Addition to Hormonal Theory 19. E2709 Quality of Life in Younger Breast cancer Survivors

3 3 2. Central Nervous System Tumors 1. E1F05 Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma 2. N0574 Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases 3. Gastrointestinal Cancers A. Colorectal Cancer 1. N0147 A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5- FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer 2. S0518 Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients 3. S0600 Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC ) with or without Bevacizumab (NSC ) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, or XELOX 4. Phase III Trial of Cetuximab, Bevacizumab and 5FU/Leucovorin Versus Oxaliplatin, Bevacizumab and 5FU/Leucovorin in Metastatic Colorectal Cancer (Monterey Bay Oncology) 5. E5202 Phase III 5-FU Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers 6. C80405 Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation 7. E3204 Phase II Study of Preoperative Radiation with Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients with Locally Advanced Rectal Cancer 8. E3205 Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and Radiation in Immunocompetent Patients with Anal Carcinoma 9. E4203 Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer 10. E5204 Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation 11. NSABP R04 Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Flourouracil (5- FU) in the Treatment of Patients with Operable Carcinoma of the Rectum

4 4 B. Esophageal Cancer 1. CALGB 80101Phase III Adjuvant Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer 2. S0356 Oxaliplatin Plus Protracted Infusion 5-Fluorouracil and Radiation for Potentially Curable Esophageal Cancer: A Phase II Trial with Molecular Correlates 3. C Phase II Study of ECF-C, IC-C, or Folfox-C in Metastatic Esophageal and GE Junction cancer 4. E2202 Minimally Invasive Esophagectomy (MIE): A Multicenter Feasibility Study C. Pancreatic Cancer 1. S0727 A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC ) + IMC-A12 (NSC ) vs. Gemcitabine + Erlotinib as First Line Treatment in Patients with Metastatic Pancreatic Cancer 4. Gynecologic Cancers A. Ovarian / Peritoneal Cancer 1. GOG 0198 A randomized study of Tamoxifen vs Thalidomide in Patients with Biochemical Recurrence- only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After Chemotherapy 2. IBCSG-2402 Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT) B. Uterine Cancer 1. GOG0209 Trial of Doxorubicin (Adriamycin)/Cisplatin (Platinol)/Paclitaxel (Taxol)/ G-CSF (Neupogen) vs Carboplatin/Paclitaxel in Patients with State III & IV or Recurrent Endometrial Cancer 5. Head & Neck Cancer 1. E1302 Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) In Performance Status 2 Or Previously Treated Patients With Recurrent Or Metastatic Head And Neck Cancer

5 5 2. E1304 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (VELCADETM) in Combination with Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients with Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) 6. Lung 1. CALGB Phase III Randomized Trial Of Lobectomy Versus Sublobar Resection For Small Peripheral Non-Small Cell Lung Cancer 2. E1504 Phase II Study of C225 (Cetuximab) for the Treatment of Patients with Advanced Bronchioloalveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features 3. E1505 Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>/= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC) 4. E5501 Phase II Study: Sequencing Topoisomerase Inhibitors for EXtensive Stage Small Cell Lung Cancer (SCLC); Topotecan Sequenced with Etopside/Cisplatin, and Irinotecan/Cisplatin Sequenced with Etoposide 5. E5597 Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer Phase III Comparison of Thoracic Radiotherapy Regimens with Cisplatin and Etoposide in Limited Small Cell Lung Cancer 7. RTOG 0617 Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer 8. S0229 Randomized Trial Assessing the Effects of Exercise on Patients with Locally Advanced Lung Cancer Undergoing Curative Intent Combined Modality Therapy 9. S0424 Molecular Epidemiology Case-Series of Non-small Cell Lung Cancer in Smoking and Non-Smoking Women and Men 10. S0429 Phase I Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer 11. S0526 Phase II Trial of Pemetrexed in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) 12. S0533 Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC ) in Three Cohorts of Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer 13. S0635 Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC ) and Bevacizumab (Rhumab VEGF; NSC ) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features 14. S0636 Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC ) and Bevacizumab (Rhumab VEGF; NSC ) in Never-Smokers with Stage IIIB and IV Primary NSCLC Adenocarcinomas 15. S9925 Lung Cancer Specimen Repository Protocol, Ancillary

6 6 7. Melanoma 1. E1602 Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T- Cells and Helper T-Cells for Patients with Metastatic Melanoma 2. E1697 Phase III Randomized Study of Four Weeks High Dose IFN-A2B in Stage T2B NO, T3A- B NO, T4A-B NO, and T1-4, N1A, 2A, 3 (microscopic) Melanoma 3. E2602 Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor 4. E2603 Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel, and BAY versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma 5. S0438 Phase II Trial of BAY (Sorafenib; NSC ) with Either CCI-779 (Temsirolimus; NSC ) or R (Tipifarnib; NSC ) in Metastatic Melanoma and Assessment of the Role of PET Imaging for Evaluation as an Early Indicator of Response 6. S0512 Phase II Trial of BAY (Sorafenib; NSC ) in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma 7. S0008 Phase III Trial of High Dose Interferon Alpha 2b vs Cisplatin, Vinblastine, DTIC +IL-2 and Interferon in Patients with High Risk Melanoma 8. Prostate Cancer 1. SWOG0421 Phase III Trial of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer 2. Phase III DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) (Monterey Bay Oncology) 3. C90202 Randomized, Double Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone 4. C90203 Randomized Phase III Study of Neoadjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer 5. C90401 Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab (IND #7921, NSC #704865) in Men with Hormone Refractory Prostate Cancer 6. MDA 3410 Randomized Phase III Trial Comparing Consolidation Therapy with or without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer 7. S9346 Phase III Study of Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer 8. R0415 Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer

7 7 9. R0521 Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High- Risk Prostate Cancer 10. S0354 Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6) in Patients with Hormone Refractory Prostate Cancer 11. E7389 Phase II in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy 12. E3803 Phase II Study of a Weekly Schedule of BMS for Patients with Hormone Refractory Prostate Cancer 13. E3805 ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer 14. E5805 Phase II Trial of E7389 (Halichondrin B Analog), in Patients with Metastatic Hormone Refractory Prostate Cancer 15. E9802 Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM with GM-CSF in Patients with PSA Progression After Local Therapy for Prostate Cancer 16. S0437 Prostate Cancer Prevention Trial (PCPT) Companion Long Term Follow Up Study for Men Diagnosed with Prostate Cancer 17. PR11 Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer (START) A. Bladder 9. Urologic Cancers (other) 1. S0337 Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer 2. S0353 Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG 3. R0233 Phase II Randomized Trial for Patients with Muscle-invading Bladder Cancer Evaluating Transurethral Surgery and Bid Irradiation Plus Either Pacitaxel and Cisplatin Followed by Selective Bladder Preservation and Gemcitabine/Paclitaxel/Cisplatin Adjuvant Chemotherapy 4. R0524 Phase I/II Trial of a Combination of Paclitaxel and Trustuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery For Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer B. Kidney Cancer 1. E2805 Phase III Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery

8 8 2. E2804 Phase II Study of VEGF, RAF kinase and mtor Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma C. Urethral 1. E1804 Phase II Trial of Sorafenib (BAY ) (IND 69896; NSC ) in Patients with Advanced Urothelial Cancer II. Hematologic Cancers 1. Leukemia 1. CALGB10501 Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized To Early Intervention Versus Observation with Later Treatment in the High risk Genetic Subset with IGVh Unmutated Disease 2. E1010 C Phase II Trial of Intravenous Pentostatin For the Treatment of Patients with Refractory Chronic Graft-Versus-Host Disease 3. E1900 Phase III Trial in Adult Acute Myeloid Leukemia:Daunorubicin Dose Intensification and Gemtuzumab-Ozogamicin Consolidation Therapy Prior to Autologous Stem Cell Transplantation 4. E1902 Phase II Study of Reduced Intensity Allogeneic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes 5. E1904 Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase, and Dexamethasone) with Subcutaneous Campath (NSC ) for Adults with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) 6. E1905 Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia 7. E2902 Phase III Randomized Study of Farnesyl Transferase Inhibitor R in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or Remission after Primary Induction Failure or Patients over Age 60 in First Remission 8. E2903 Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (PCR) Followed By Campath-1H For Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia 9. E3903 Ancillary laboratory protocol for collecting diagnostic material on patients considered for ECOG treatment trials for leukemia or related hematologic disorders 10. E5998 Phase II Study of Initial Treatment with Methotrexate in Large Granular Lymphocytic (LGL) Leukemia

9 9 11. E0325 Phase IIb Study of Molecular Responses to Imatinib at Standard or Increased, or Dasatinib (BMS ) (NSC ), for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase 12. S0333 Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy 13. S0521 Phase III Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL) 14. S0530 Phase II Trial of Cytarabine and Clofarabine in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia 15. S0535 Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia 16. S0605 Phase II Study of Lenalidomide (Revlimid ) (NSC ) for Previously Untreated Non- M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy 17. S0106 Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg ) Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg ) or No Additional Therapy for Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL) Phase II Study of Three Fludarabine/Antibody Combinations for Patients with Symptomatic Previously Untreated Chronic Lymphocytic Leukemia 20. SWOG 9007 Cytogenetic Studies in Leukemia Patients 21. S9910 Leukemia Centralized Reference Laboratories and Tissue Repositories 2. Lymphoma 1. CALGB Phase III Randomized Study of R-CHOP v. Dose-adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas 2. CTN 0401 Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin s Lymphoma 3. E1405 Phase II Study of VcR-CVAD with Rituximab Maintenance for Untreated Mantle Cell Lymphoma 4. E2402 Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma 5. E2404 Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms 6. E3402 Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma 7. E3404 Response-Adapted Therapy for Aggressive non-hodgkin's Lymphomas based on early [18F] FDG-PET Scanning

10 10 8. E4402 Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumor Burden Indolent non-hodgkin's Lymphoma 9. S0016 Phase III Trial of CHOP + Rituximab vs CHOP + Iodine-131-Labeled Monoclonal Anti- B1 Antibody (Tositumomab) For Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas 10. S0313 Phase II Evaluation of CHOP Plus Involved Field Radiotherapy followed by Yttrium- 90 Ibritumomab Tiuxetan for Stages I, IE and non-bulky Stages II and IIE, CD20 Positive, High-risk Localized, Aggressive Histologies of Non-Hodgkin's Lymphoma 11. S0350 Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma 12. S0410 Phase II Trial of Tandem Autologous Stem Cell Transplantation For Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study). 13. S0433 Phase II Trial of Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Diffuse Large B-Cell NHL 14. S0515 Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B- Cell NHL 15. S0520 Phase II Study of PXD101 (NSC ) in Relapsed and Refractory Aggressive B-Cell Lymphomas 16. S0601 Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade ) (R- CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients With Newly Diagnosed Mantle Cell Lymphoma 17. SWOG8819 Central Lymphoma Repository Tissue Procurement Protocol 18. SWOG 8947 Central Lymphoma Serum Repository Protocol 19. SWOG 9245 Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease, Ancillary 20. An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma (Monterey Bay Oncology) 3. Myeloma Phase III Randomized Double-Blind Study of Maintenance Therapy with CC-5013 or Placebo Following Autologous Stem Cell Transplantation for multiple Myeloma 2. E1A05 Phase III Trial of Consolidation Therapy with Bortezomib(Velcade), CC-5013 & Dexamethasone(VRD) VS. Bortezomib(Velcade) & Dexamethasone(VD) for Patients With Multiple myeloma who have completed a Dexamethasone Based Induction Regimen 3. E1A06 An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) versus Melphalan, Prednisone and Lenalidomide (Revlimid)(MPR) in Newly Diagnosed Myeloma Patients Who Are Not Candidates for High Dose Therapy 4. E3A05 Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for Studies of Plasma Cell Disorders 5. S0115 Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) And Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) For Patients with AL Amyloidosis or High Risk (greater than or equal to Age 70 or Poor Renal Function)Patients With Multiple Myeloma(A BMT Study)

11 11 6. S0120 Prospective Observational Biologic Study of Asymptomatic Patients With Monoclonal Gammopathy and Plasma Proliferative Disorders 7. S0309 Myeloma Specimen Repository Protocol 8. S0434 Phase II Trial of BAY (Sorafenib) (NSC ) in Patients with Relapsing or Resistant Multiple Myeloma 9. S0777 Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC and Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC ), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant 10. JMY10 Phase III Study of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma 11. U1099 Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma III. Other 1. E1Y03 Master Protocol for Pharmacogenetic and Genomic Studies